PMD updates on the reverse share split following the reverse acquisition
Kurs
+13,17%
Likviditet
0,12 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-26 | N/A | Bokslutskommuniké 2024 |
| 2024-11-29 | N/A | Kvartalsrapport 2024-Q3 |
| 2024-10-29 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2024-05-29 | - | Årsstämma |
| 2024-05-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2024-01-31 | - | Split PMDS 128:1 |
| 2023-12-29 | - | Extra Bolagsstämma 2023 |
| 2023-11-28 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-30 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-27 | - | Årsstämma |
| 2023-05-24 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-29 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-30 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2022-05-17 | - | Årsstämma |
| 2022-05-17 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-23 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-05-27 | - | Extra Bolagsstämma 2021 |
| 2021-05-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-23 | - | Bokslutskommuniké 2020 |
| 2020-11-24 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-25 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-26 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-18 | - | Bokslutskommuniké 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-10-22 | - | Extra Bolagsstämma 2019 |
| 2019-08-27 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-22 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2019-05-21 | - | Årsstämma |
| 2019-05-21 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-26 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-20 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning PMDS 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-06 | - | Bokslutskommuniké 2017 |
| 2017-11-21 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-30 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
PMD Device Solutions AB ("PMD" or the "Company") formerly Promore Pharma AB, carried out the reverse acquisition with the PMD group by decision of the extraordinary general meeting on 29 December 2023 and simultaneously decided on a reverse share split (1:128).
The extraordinary general meeting authorised the board of directors to determine the record date for the reverse split which is expected to be resolved upon during the month of January. The Board will, in connection with the determination of the record date for the reverse split, publish further information on the procedure for the reverse split.
For additional information, please contact:
Myles Murray, CEO
Phone: +353 86 887 4994
E-mail: myles@pmd-solutions.com; for general enquiries investor.relations@pmd-solutions.com
The Company’s Certified Adviser is Redeye.
Information about PMD
PMD develops and sells medical products for respiratory monitoring. Its primary product is RespiraSense™, a solution used for monitoring respiratory rate to detect deterioration of a patient’s general condition early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense™ is, to the PMD’s knowledge, the world’s only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. PMD received FDA approval for RespiraSense™ in 2022. RespiraSense™ is a novel technology and today used in 25 hospitals across United Kingdom and Ireland. PMD seeks to continue increasing its market share in the United Kingdom, with Germany and the United States to follow with initial market access activities. The Company is listed on Nasdaq First North Growth Market.
For additional information, please contact
Myles Murray, CEO
Phone: +353 86 887 4994
E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com
The Company’s Certified Adviser is Redeye.
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of locally administered first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. The company is listed on Nasdaq First North Growth Market.